Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: A randomised, double-blind, placebo-controlled trial

The Lancet Infectious Diseases

Volumn 15, Issue 12, 2015, Pages 1389-1397

  Bines, Julie E ^a,b,c   Danchin, Margaret ^a,b,c   Jackson, Pamela ^d   Handley, Amanda ^a   Watts, Emma ^a   Lee, Katherine J ^a,b   West, Amanda ^d   Cowley, Daniel ^a,b   Chen, Mee Yew ^d   Barnes, Graeme L ^a,b   Justice, Frances ^a   Buttery, Jim P ^a,c,e,g   Carlin, John B ^a,b   Bishop, Ruth F ^a,b   Taylor, Barry ^d   Kirkwood, Carl D ^a,b,f   Boniface, Karen ^a   Bogdanovic Sakran, Nada ^a   Pavlic, Dan ^a   Siero, Will ^a   Standish, Jane ^a,b,c,e,g   Barker, Catherine ^d   Hough, Nicola ^d   Columb, Jane ^d   McCaffrey, Frances ^d   McGhie, Andria ^d   Reith, David ^d   more..

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e MONASH MEDICAL CENTRE   (Australia)

^f LA TROBE UNIVERSITY   (Australia)

^g MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; PLACEBO; ROTAVIRUS VACCINE; LIVE VACCINE; RV3 ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ABDOMINAL DISCOMFORT; ANTIBODY BLOOD LEVEL; ARTICLE; ASYMPTOMATIC DISEASE; BILIRUBIN BLOOD LEVEL; BIRTH WEIGHT; BRONCHIOLITIS; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; CRYING; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REGIMEN; DRUG SAFETY; ECZEMA; FAILURE TO THRIVE; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEMANGIOMA; HUMAN; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; INFANTILE COLIC; IRRITABILITY; JAUNDICE; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEWBORN; PEDIATRICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; ROTAVIRUS INFECTION; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STEATORRHEA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINATION; VIRUS INFECTION; VIRUS LOAD; VIRUS SHEDDING; VOMITING; BLOOD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; NEW ZEALAND; ROTAVIRUS; ROTAVIRUS INFECTIONS; VIROLOGY;

ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; INFANT; INFANT, NEWBORN; MALE; NEW ZEALAND; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 84960392750     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00227-3     Document Type: Article

References (36)

1. Fernandes EG, Sato HK, Leshem E, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations in Sao Paulo State, Brazil. Vaccine 2014, 32:3402-3408.
2. Bar-Zeev N, Kapanda L, Tate JE, et al. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. Lancet Infect Dis 2015, 15:422-428.
3. Rha B, Tate JE, Weintraub E, et al. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines 2014, 13:1339-1348.
4. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis 2011, 15:e206-e210.
5. Richardson V, Parashar U, Patel M Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011, 365:772-773.
6. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
7. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
8. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
9. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
10. Chan J, Nirwati H, Triasih R, et al. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries?. Vaccine 2011, 29:1242-1247.
11. Kosek M, Guerrant RL, Kang G, et al. Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework. Clin Infect Dis 2014, 59(suppl 4):S239-S247.
12. Groome MJ, Moon SS, Velasquez D, et al. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. Bull World Health Organ 2014, 92:238-245.
13. Carlin JB, Macartney KK, Lee KJ, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis 2013, 57:1427-1434.
14. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29:3061-3066.
15. Glass RI, Parashar UD Rotavirus vaccines-balancing intussusception risks and health benefits. N Engl J Med 2014, 370:568-570.
16. Tiku VR, Sharma S, Verma A, et al. Rotavirus diversity among diarrheal children in Delhi, India during 2007-2012. Vaccine 2014, 32(suppl 1):A62-A67.
17. Mathew A, Rao PS, Sowmyanarayanan TV, et al. Severity of rotavirus gastroenteritis in an Indian population: report from a 3 year surveillance study. Vaccine 2014, 32(suppl 1):A45-A48.
18. Global routine vaccine coverage, 2011. Wkly Epidemiol Rec 2012, 44:432-433. WHO.
19. Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983, 309:72-76.
20. Bishop RF, Unicomb LE, Barnes GL Epidemiology of rotavirus serotypes in Melbourne, Australia, from 1973 to 1989. J Clin Microbiol 1991, 29:862-868.
21. Danchin M, Kirkwood CD, Lee KJ, et al. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine 2013, 31:2610-2616.
22. Bishop RF, Bugg HC, Masendycz PJ, et al. Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. J Infect Dis 1996, 174(suppl 1):S22-S29.
23. Coulson BS, Fowler KJ, Bishop RF, et al. Neutralizing monoclonal antibodies to human rotavirus and indications of antigenic drift among strains from neonates. J Virol 1985, 54:14-20.
24. Elschner M, Prudlo J, Hotzel H, et al. Nested reverse transcriptase-polymerase chain reaction for the detection of group A rotaviruses. J Vet Med B Infect Dis Vet Public Health 2002, 49:77-81.
25. Newcombe RG Interval estimation for the difference between independent proportions: comparsion of eleven methods. Stat Med 1998, 17:873-890.
26. Patel M, Glass RI, Jiang B, et al. A systemic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013, 208:284-294.
27. Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010, 28:5272-5279.
28. Anderson EJ Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008, 8:642-649.
29. Dennehy PH, Goveia MG, Dallas MJ, et al. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007, 11(suppl 2):S36-S42.
30. Hseih YC, Wu FT, Hsiung CA, et al. Comparison of virus shedding after live attenuated and pentavalent reassortant rotavirus vaccine. Vaccine 2014, 32:1199-1204.
31. Justice F, Carlin J, Bines J Changing epidemiology of intussusception in Australia. J Paediatr Child Health 2005, 41:475-478.
32. Vesikari T, Karvonen A, Forrest BD, et al. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006, 25:118-122.
33. Armah GE, Kapikian AZ, Vesikari T, et al. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J Infect Dis 2013, 208:423-431.
34. Ruuska T, Vesikari T, Delem A, et al. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic season. Scand J Infect Dis 1990, 22:269-278.
35. Bhandari N, Rongesen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo controlled trial. Lancet 2014, 383:2136-2143.
36. Steele AD, Page N, de Beer M, et al. Antigenic and molecular characterization of unusual rotavirus strains in Burkina Faso in 1999. J Infect Dis 2010, 202(suppl):S225-S230.